

Attorney Docket No.: **DEX0489US.NP**  
Inventors: **Duan et al.**  
Serial No.: **10/558,543**  
Filing Date: **October 23, 2006**  
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claim 1-19 (canceled)

Claim 20 (currently amended): A kit ~~for diagnosing a patient's susceptibility to prostate cancer or ovarian cancer comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring CA125 levels wherein the levels of Cln101 are determined.~~

Claim 21-23 (canceled)

Claim 24 (currently amended): ~~An isolated Cln101 antibody that~~ The antibody of claim 30 which binds to mammalian Cln101 in vivo or in vitro.

Claim 25 (currently amended): The antibody of claim 24 claim 30 which internalizes upon binding to Cln101 on a mammalian cell in vivo.

Claim 26 (currently amended): The antibody of claim 24 claim 30 which is a monoclonal antibody, an antibody fragment or a chimeric or a humanized antibody.

Claims 27-28 (canceled)

Claim 29 (original): The antibody of claim 26 which is produced by a hybridoma selected from the group consisting

Attorney Docket No.: **DEX0489US.NP**  
Inventors: **Duan et al.**  
Serial No.: **10/558,543**  
Filing Date: **October 23, 2006**  
Page 4

of American Type Culture Collection accession number PTA-5877 and PTA-5876.

Claim 30 (currently amended): ~~The antibody of claim 24,~~  
~~wherein the~~ An isolated antibody which competes for binding  
to the same epitope as the epitope bound by the monoclonal  
antibody produced by a hybridoma selected from the group  
consisting of ATCC accession number PTA-5877 and PTA-5876.

Claim 31 (currently amended): The antibody of ~~claim 24~~ claim  
30 which is conjugated to a growth inhibitory agent or a  
cytotoxic agent.

Claim 32-44 (canceled)

Claim 45 (currently amended): ~~A cell~~ An isolated cell that  
produces the antibody of claim 26.

Claim 46 (original): The cell of claim 45, wherein the cell  
is selected from the group consisting of hybridoma cells  
deposited under American Type Culture Collection accession  
number PTA-5877 and PTA-5876.

Claim 47 (canceled)

Claim 48 (currently amended): A composition comprising the  
antibody of ~~claim 24~~ claim 30, and a carrier.

Claim 49-50 (canceled)

Attorney Docket No.: **DEX0489US.NP**  
Inventors: **Duan et al.**  
Serial No.: **10/558,543**  
Filing Date: **October 23, 2006**  
Page 5

Claim 51 (original): The composition of claim 48, wherein the antibody is a human or humanized antibody and the carrier is a pharmaceutical carrier.

Claim 52-94 (canceled)

Claim 95 (currently amended): ~~The kit of claim 20 for diagnosing a patient's susceptibility to prostate cancer further A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the levels of both PSA and Cln101 are determined assay for Cln101 comprises the antibodies of claim 30.~~

Claim 96 (new): The antibody of claim 30 which is detectably labeled.

Claim 97 (new): The antibody of claim 96 wherein the label is selected from the group comprising radioisotope, fluorescent, enzymatic, biotin, and gold particle labels.